We have been instrumental in the discovery of four drugs now on the market
We leverage our accomplishments in drug discovery with our determination to remain at the cutting edge of research to deliver innovation for industry and academia. As your partner, we provide you with robust and cutting edge scientific expertise, honed in global pharma, along with the steadfast support required in a fast-paced and challenging industry.
Science is our cornerstone. Our unprecedented track record in discovering drugs demonstrates this. We capitalize on our shared enthusiasm for innovative R&D, spurred on by our dedication to deliver excellence at every opportunity.
Our expertise spans different modalities including small molecule, peptide and biologic therapeutics. With a passionate, interdisciplinary and accomplished team, and capabilities ranging from target validation to clinical candidate nomination, we bring great science to your project.
Our partners are of the utmost importance. We always strive to go above and beyond your expectations, treating your projects as our highest priority.
We offer a unique blend of broad scientific expertise, global pharma heritage, and unprecedented success in bringing drug discovery projects from conception to the clinic. With a passionate, interdisciplinary and accomplished team, and capabilities ranging from target validation to clinical candidate nomination, we bring great science to your project.
Come and meet our great team attending the 17th Annual Drug Discovery Chemistry conference in person and taking place from April 18-21 in San Diego.
The conference is focused on the discovery and optimization challenges of small molecule drug candidates, with attendance by leading researchers from academia, government, biotech, pharma and healthcare.
IRBM’s team will be in Seattle for the 35th International Conference on Antiviral Research #ICAR 2022 March 21-25, 2022. If…
The Power of NMR in Drug Discovery
Structural biology (SB) provides a critical drug discovery and development tool for accurately identifying and understanding the structure of a target. Alessandro Piai, PhD, Principal Research Scientist at IRBM, describes the company’s expertise in nuclear magnetic resonance (NMR) and how it can be leveraged to accelerate the identification of molecules for progression to the clinic.